CYTH (Cyclo Therapeutics, Inc) Forward P/S Multiple

Risks for Cyclo Therapeutics (CYTH) are linked to potential trial failures and competition from gene therapy. Patents on molecules and strict FDA oversight serve as defensive qualities. This chart on GURU.Markets includes a forward P/S indicator, where 23.60 shows the current value of the metric. This price action reflects a stable vote of confidence in management during the adaptation period of clinical programs.

Cyclo Therapeutics, Inc. - CYTH Forward P/S Multiple (period 07/04/2022 - 04/05/2025)

Summary analytical data breakdowns for Cyclo Therapeutics, Inc (CYTH)

- market price and analyst price targets:

Price Chart Cyclo Therapeutics, Inc.|CYTH - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization Cyclo Therapeutics, Inc|CYTH - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Cyclo Therapeutics|CYTH - Book Capitalization|Market Value to Book Value Ratio cyclotherapeutics.com|CYTH - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

CYTH - Net Income|Expected Profit Cyclo Therapeutics|CYTH - Price to Earnings Ratio|Future Price to Earnings CTD Holdings|CYTH - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Cyclo Therapeutics, Inc|CYTH - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Cyclo Therapeutics|CYTH - Earnings per share for the last four quarters|Quarterly EPS earnings growth cyclotherapeutics.com|CYTH - Earnings per share increase in current year|Earnings growth forecast for next year Cyclo Therapeutics

- total revenue and sales volume data:

CYTH - Company Total Revenue|Company Projected Revenue Cyclo Therapeutics, Inc.|CYTH - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Cyclo Therapeutics, Inc

Fundamental company analysis:Cyclo Therapeutics, Inc. CYTH

Original product of Cyclo Therapeutics, Inc

For the biotech sector, the forward price-to-sales valuation dynamics of Cyclo Therapeutics (CYTH) serve as an indicator of market expectations regarding the monetization of orphan drugs. This metric is calculated as the ratio of current market capitalization to projected annual revenue, allowing for a real-time assessment of the value of scientific competencies and the clinical trial expert staff, bypassing the lengthy intervals between quarterly reports.

Competitors of Cyclo Therapeutics (CYTH)

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ARCT (Arcturus Therapeutics)|Forward P/S Multiple etonpharma.com ETON|Kamada - Forward P/S Multiple|Fulcrum Therapeutics Inc (FULC) - Forward Price-to-Revenue Multiple|ABEO (abeonatherapeutics.com) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Mereo BioPharma Group plc (MREO)|PLX (Protalix BioTherapeutics) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Pliant Rx (PLRX)|Price-to-Projected Revenue Ratio Applied Therapeutics, Inc. (APLT)|Price-to-Projected Revenue Ratio RNTX (Rein Therapeutics Inc.)|Price-to-Projected Revenue Ratio Gelteq GELS|Aytu BioPharma Inc (AYTU) - Market Cap to Future Revenue Ratio|CMMB: Forward Price-to-Revenue Multiple|Forward Price to Sales SRXH (SRx Health Solutions Inc.)|PLRZ (polyrizon-biotech.com) - Forward Price-to-Revenue Multiple|AEZS: Price to Expected Revenue Ratio|INZY (Inozyme Pharma Inc.) - Forward P/S Multiple|RPHM: Forward Price to Sales|Forward P/S Multiple CSCI